Charles is a highly experienced corporate finance lawyer with extensive experience in advising biotech, medtech, tech and pharma clients on equity financings, IPOs, mergers, and other corporate transactions.

Charles has acted for a wide range of clients, including startups and university spinouts on seed financings, early-stage companies on Series A rounds, biotech companies on IPOs and secondary financings, venture capital funds investing in unlisted biotech companies, pharma companies taking strategic stakes in unlisted biotech companies, selling shareholders in biotech and medtech companies on private M&A transactions, and public company takeovers of biotech and medtech companies.

Charles regularly mentors companies participating in the Biotech Industry Association Pulse Programme and KQ Labs Accelerator Programme.

  • “Very, very good and has a familiarity with the [life sciences] sector which meant we could dispense with the niceties and get down to business."

    Chambers 2024

  • “Charles Waddell excels in high-profile transactions assisting with biotech and medtech financings.”

    The Legal 500 2023